October 6, 2023
Kaken Pharmaceutical said on October 5 that its primary axillary hyperhidrosis treatment Ecclock (sofpironium bromide) has been filed for regulatory approval in South Korea by local partner Dong-Wha Pharm. The submission was made on September 27 to the Ministry of...read more